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Abstract
Background: Toll-like receptors (TLRs) are a family of pattern-recognition receptors, which plays a role in eliciting
innate/adaptive immune responses and developing chronic inflammation. The polymorphisms of TLRs have been
associated with the risk of various autoimmune diseases, including systemic lupus erythematosus (SLE), multiple
sclerosis and rheumatorid arthritis. The aim of this study was to evaluate whether TLR genes could be used as
genetic markers for the development of Graves’ ophthalmopathy (GO).
Methods: 6 TLR-4 and 2 TLR-9 gene polymorphisms in 471 GD patients (200 patients with GO and 271 patients
without GO) from a Taiwan Chinese population were evaluated.
Results: No statistically significant difference was observed in the genotypic and allelic frequencies of TLR-4 and
TLR-9 gene polymorphisms between the GD patients with and without GO. However, sex-stratified analyses
showed that the association between TLR-9 gene polymorphism and GO phenotype was more pronounced in the
male patients. The odds ratios (ORs) was 2.11 (95% confidence interval [CI] = 1.14-3.91) for rs187084 AàG
polymorphism and 1.97 (95% CI = 1.07-3.62) for rs352140 AàG polymorphism among the male patients. Increasing
one G allele of rs287084 and one A allele of rs352140 increased the risk of GO (p values for trend tests were 0.0195
and 0.0345, respectively). Further, in haplotype analyses, the male patients carrying the GA haplotype had a higher
risk of GO (odds ratio [OR] = 2.02, 95% confidence interval [CI] = 1.09-3.73) than those not carrying the GA
haplotype.
Conclusion: The present data suggest that TLR-9 gene polymorphisms were significantly associated with increased
susceptibility of ophthalmopathy in male GD patients.
Background
Graves’ disease (GD) is an organ-specific autoimmune
thyroid disease, one of the manifestations of which is
ophthalmopathy [1]. Graves’ ophthalmopathy (GO) is
characterized by inflammation and fat deposition in the
eye muscles and the connective tissue surrounding the
eye. It is known that multiple factors contribute to the
etiology and severity of GD, including the host’s genetic
factors as well as environmental factors [2,3]. Female
sex, old age, and smoking history are common risk fac-
tors for GD [4-8]. With regard to genetic factors, the
classical major histocompatibility complex class II genes
and cytotoxic T cell antigen-4 genes (CTLA-4) [9-11]
have been consistently reported to be associated with
GD. Also, there were published studies on association of
GO and genes such as CD103 [12], CTLA-4 and IL-13
[13]. However, the findings of most genes effect in GD
or GO were inconsistent. Recently, toll-like receptors
(TLRs) which play important roles in eliciting human
innate/adaptive immune responses and developing
chronic inflammation [14] are a new area of basic
immunological investigation and could be associated
with autoimmune thyroiditis [15].
TLRs are a family of pattern-recognition receptors and
can be expressed in several types of cells and tissues
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such as macrophages, dendritic cells (DCs), B cells,
T cells and monocytes. A total of 10 human TLRs have
been identified and the functions of human TLR-1 to
TLR-9 have been characterized [16,17,14,15]. TLRs are
well known to recognize a variety of microbial mole-
cules such as TLR-4 can recognize lipopolysaccharides
(LPSs) in gram-negative bacteria and TLR-9 activation
can be triggered by unmethylated CpG DNA of bacteria.
Once TLRs are activated by microbial molecules, down-
stream signalling pathway via myeloid differentiation
factor 88 (MyD88) and interleukin-1R (IL-1R)-associated
kinase (IRAK) activates nuclear factor B (NF-B), lead-
ing to cytokine production, and even to apoptosis. TLRs
could response to not only exogenous, microbe derived
pathogen associated molecular patterns (PAMPs) but
also endogenous or self ligands. Recently, the ability of
TLRs to recognize host-derived danger signals, which
are produced on cell damage and necrosis, was also
recognized [18,19]. Moreover, studies have found that
the immune complexes containing self-RNA and/or self-
DNA can act as endogenous triggers for the activation
of TLRs [20-22].
Recently, release of endogenous TLR ligands during
inflammation and the consequent activation of TLR sig-
naling pathways have been indicated and polymorphism
of the TLR4 and TLR9 gene have been reported to be
associated with many autoimmune diseases, such as sys-
temic lupus erythematosus (SLE), atherosclerosis,
asthma, type 1 diabetes, multiple sclerosis, and rheuma-
toid arthritis (RA) [14,23-31]. However, to the best of
our knowledge, there were no reports about TLR4 and
TLR9 in GO. Therefore, our aim in the present study
was to investigate the potential association between GO
and single-nucleotide polymorphisms (SNPs) of TLR
genes–TLR-4 and TLR-9 genes–in a Chinese population
in Taiwan.
Methods
Patients and data collection
Four hundred and seventy one GD patients at China
Medical University Hospital in Taiwan were enrolled in
present study. All GD patients were examined by experi-
enced endocrinologist and identified using following cri-
teria: having hyperthyroidism, having diffused goiter and
presence at least one of thyroid-stimulating hormone
(TSH) receptor antibody, diffusely increased 131I
(iodine-131) uptake in the thyroid gland or presence of
exophthalmos. The proptosis was quantified with an
exophthalmometer. The data regarding age, sex, history
of tobacco use, thyroid gland pathology and affected
anatomic sites were extracted from the questionnaire
and blood samples were collected by venipuncture for
genomic DNA isolation and serological test at the
enrollment in study. Informed consent was obtained
from each participant before his/her inclusion in
this study and the ethics committee of China Medical
University Hospital gave its approval for the study.
Genomic DNA extraction and genotyping
The genomic DNA was extracted from peripheral blood
leukocytes of GD patients using the Genomic DNA kit
(Qiagen) according to the manufacturer’s instructions.
To select the most representative single nucleotide poly-
morphisms (SNPs) by capturing the majority genetic
variation, SNP genotype information was downloaded in
December 2008 from the HapMap Han Chinese in Beij-
ing (HCB) and Japanese in Tokyo (JPT) population.
HapMap genotypes were analyzed within Haploview and
Tag SNPs were selected using the Tagger function. The
following criteria were used to select Tag SNPs: (1) a
threshold minor allele frequency (MAF) of 0.10 (2) mul-
timarker method with r2 threshold >0.8 and logarithm
of odds threshold 3.0 (3) probe or primers that pass the
qualification as recommended by the manufacturer
(Applied Biosystems Inc., Foster City, CA) to ensure a
high genotyping success rate. The mean max r2 were
0.949 and 1 for TLR4 and TLR9 SNPs, respectively. A
total of six SNPs for TLR-4 and 2 SNPs for TLR-9, were
selected in present study. Genotyping was achieved
using an assay on-demand allelic discrimination assay
and detection system according to the manufacturer’s
instructions (Applied Biosys tems). Briefly, polymerase
chain reaction (PCR) was performed in the presence of
10 ng genomic DNA, 10 μl TaqMan master mix, and
0.125 μl of 40x assay mix. Polymerase chain reaction
analysis was performed in 96-well plates on a thermal
cycler (ABI 9700; Applied Biosystems). Reaction condi-
tions were 50°C for 2 minutes and 95°C for 10 minutes,
followed by 40 cycles at 95°C for 15 seconds and 60°C
for 1 minute. Real-time detection of fluorescence signals
was performed using the ABI Prism 7900 Real-Time
PCR System. The frequency of SNPs’ genotype for HCB
+ JPT population was extracted from PubMed [32-36].
Statistical analysis
The difference of genotypic and allelic frequencies dis-
tributions between GD patients with and without
ophthalmopathy and between GD patients and indivi-
duals information from HCB-HapMap were analyzed by
the c2 test or Fisher exact test. The odds ratio (OR) was
calculated from genotypic and allelic frequencies with
95% confidence interval (CI) by using unconditional
logistical regression adjusting for age of diagnosis, gen-
der and smoking history. We further stratified data into
subgroups by sex and homogeneity test were performed
to determine whether the association between genotype/
haplotype frequencies and GO phenotype is similar in
males and females two groups. If the homogeneity test
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was significant, the different association in males and
female was indicated. Then males and females two
groups should be analyzed separately. All statistical ana-
lyses were conducted using SAS statistical software, ver-
sion 9.1 (SAS Institute Inc., Cary, NC). All tests were
two-sided, and a p value less than 0.05 was used as the
level of significance.
Power calculation
The power calculation was based on the following
assumptions: the allele frequencies of the investigated
SNPs within the population were based on the informa-
tion from HapMap-CHB (0.422 to 0.675 for TLR9 SNPs
and 0.067 to 0.633for TLR4 SNPs) and the size of pre-
sent study were 271 for control group and 200 for case
group. Therefore, the estimated effect size of OR, 0.578
to 0.592 for TLR9 and 1.63 to 2.25 for TLR4 of the
investigated SNPs in case group can be observed using a
two independent sample test with a power of 80% at
two-sided type I error rate 0.05 (Additional file 1: table
S1).
For the effect size of TLR on GO, no formal data are
available. Therefore, we compare the observable effect
sizes from our design power calculation with the effect
sizes (OR = 0.55 to 0.56 for TLR9 and 1.78 to 2.85 for
TLR4) from previous study in RA [37]. The magnitude
of effect size in previous study in RA is bigger than our
estimated effect size. Therefore, the power will be bigger
than 80% if our effect size could be the same with the
effect size from previous study in RA. Based upon above
information, our study design could be justified.
Results
A total of 471 GD patients comprising 200 patients with
GO and 271 patients without GO were enrolled in this
study. The female to male ratio was 3.75 and the mean
age was 39.41 ± 12.42 years. There were statistically sig-
nificant differences in the GO phenotype and smoking
history between the male and female patients. The per-
centage of male and female GD patients with GO was
52% and 40%, respectively (p = 0.04). None of the fre-
quency distribution for other anatomic sites (goiter,
nodular hyperplasia, myxedema and vitiligo) was signifi-
cant different between two genders. A higher percentage
of male patients had smoking history than female
patients (66.67% vs. 12.10%, p < 0.0001) (Table 1).
Association between TLR gene polymorphism and disease
severity
We compared the allelic and genotypic frequencies of
TLR-4 and TLR-9 gene polymorphisms in the Taiwa-
nese GD patients, with the information regarding the
populations of Han Chinese in Beijing (HCB) and Japa-
nese in Tokyo (JPT) extracted from the PubMed SNP
database. The TLR-4 and TLR-9 gene polymorphisms in
the Taiwanese GD patients were not statistically differ-
ent from those in normal HCB and JPT. Further, we
classified the GD patients on the basis of the presence
of GO (Yes/No) in order to determine whether TLR-4
and TLR-9 genes were associated with the GO pheno-
type. The results did not indicate any significant differ-
ences in the TLR-4 and TLR-9 gene polymorphisms
between the GD patients with and without GO (Addi-
tional file 2: table S2 and additional file 3: table S3). All
tested SNPs were in Hardy-Weinberg equilibrium (p >
0.05).
Sex-specific effects of TLR gene polymorphisms on
susceptibility to GO
In the present study, 52% male GD patients had GO as
compared to 40% female GD patients (p = 0.04). How-
ever, there was no sex-based difference in the genotypic
distribution of TLR-4 and TLR-9 gene polymorphisms
(data not shown). Therefore, we performed sex-stratified
analyses to investigate the association between TLR
gene polymorphisms and GO phenotype in the 2 sex-
based subgroups. Statistically significant differences were
observed in the allelic frequencies of 2 SNPs of the
TLR-9 gene between the male patients with and without
GO but not in the female patients (Table 2). The odds
ratios (ORs) for rs187084 AàG polymorphism were 2.11








Yes 51 (51.52) 149 (40.05)
No 48 (48.48) 223 (59.95) 0.04
Goiter
Yes 95 (95.96) 345 (92.74)
No 4 (4.04) 27 (7.26) 0.25
Nodular hyperplasia
Yes 8 (8.08) 39 (10.48)
No 91 (91.92) 333 (89.52) 0.48
Myxedema
Yes 2 (2.02) 4 (1.08)
No 97 (97.98) 368 (98.92) 0.46
Vitiligo
Yes 1 (1.01) 3 (0.81)
No 98 (98.99) 369 (99.19) 0.84
Age at enrollment mean ± SD† 40.25 (10.62) 39.81 (12.57) 0.55†
Age at diagnosis mean ± SD† 35.69 (10.34) 34.57 (12.25) 0.16†
Smoking history
Never 33 (33.33) 327 (87.90)
Ever 66 (66.67) 45 (12.10) <0.001
Data are no. (%)
*Chi square test.
†Mann-Whitney Wilcoxon test.
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(95% confidence interval [CI] = 1.14-3.91) and 0.79 (95%
CI = 0.57-1.08) for the male and female patients, respec-
tively. The p value for homogeneity test was 0.01. For
rs352140 AàG polymorphism, the ORs were 1.97 (95%
CI = 1.07-3.62) and 0.76 (95% CI = 0.55-1.05) for the
male and female patients, respectively. The p value for
homogeneity test was 0.01. Among the male patients,
increasing one G allele of rs287084 and one A allele of
rs352140 increased the risk of GO (p values for trend
tests were 0.0195 and 0.0345, respectively). Furthermore,
we investigated the association between the TLR-9 hap-
lotype and susceptibility to GO in the male and female
patients. AG haplotype was significantly inversely asso-
ciated with susceptibility to GO (OR = 0.49, 95% CI =
0.26-0.89), while GA haplotype was significantly asso-
ciated with a high risk of GO (OR = 2.02, 95% CI =
1.09-3.73) in the male patients (Table 3). However, this
sex-specific association was not found in the case of
even one of the SNPs of the TLR-4 gene. Furthermore,
we investigated the association between various pheno-
type parameter and GO among male but no significant
association was found (Additional file 4: table S4).
Discussion
In this study, we investigated the effect of TLR-4 and
TLR-9 gene polymorphisms on the organ-specific auto-
immune disease GD in a Taiwanese population. TLR-9
polymorphisms and haplotype were significant asso-
ciated with susceptibility to GO in males. However,
none of the TLR-4 and TLR-9 polymorphism or
haplotypes was associated with overall GO risk. The
TLR4 is known to activate the NF-B and subsequent
gene expression such as cytokines and adhesion mole-
cules. A TLR-4 polymorphism that prevents ligands
binding and subsequent cellular signaling would result
in lower NF-B activation and subsequent NF-B-
dependent proinflammatory gene expression. However,
we did not find any association between TLR4 poly-
morphism and GO in present study. Low statistical
power may be the reason for this non significant results
in TLR4 association in GO. For TLR9, our results were
consistent with those of the previous studies with regard
to the association between TLR9 gene polymorphisms
and systemic autoimmune diseases, such as SLE in
Japan [30,28] and China [38,36]. From SLE model, Tao
et al study [30,28] found diminished expression of TLR9
could increase anti-dsDNA antibody in SLE mice model
which may increase the risk of developing autoimmune
disease. Also, it has been hypothesized that nucleic acid
from dying cells may act as ligands for TLR9 to trigger
IFN-1 production in SLE [39,37]. In this study, 2 TLR-9
SNPs, one (-1486TàC, rs187084) is in the promoter
region and the other (1635AàG, rs352140) is in exon 2.
The variation of TLR-9 gene in those region may down
regulate TLR9 expression and involved in production of
autoantibodies or IFN-1 which may increase the risk of
GO. Therefore, future studies are required to investigate
if variation of TLR9 gene, especially in exon region may
affect TLR9 protein expression or function which
increase the risk of GO.
Table 2 The Genotype and Allelic Frequency of TLR-9 Stratified by Sex among Graves’ Disease Patients in Taiwan
rs187084 rs352140
SNP ID with GO w/o GO P-value* OR† (95% CI) with GO w/o GO P-value* OR† (95% CI)
N (%) N (%) N (%) N (%)
Genotype
Female A/A 67 (44.97) 89 (39.91) 1 A/A 12 (8.05) 24 (10.76) 0.57 (0.26, 1.24)
A/G 71 (47.65) 108 (48.43) 0.86 (0.55, 1.34) A/G 66 (44.30) 110 (49.33) 0.73 (0.47, 1.14)
G/G 11 (7.38) 26 (11.66) 0.33 0.51 (0.23, 1.33) G/G 71 (47.65) 89 (39.91) 0.30 1
Male A/A 18 (35.29) 27 (56.25) 1 A/A 9 (17.65) 3 (6.25) 4.43 (1.04, 18.89)**
A/G 25 (49.02) 18 (37.50) 2.15 (0.91, 5.09) A/G 23 (45.10) 19 (39.58_ 1.70 (0.72, 3.99)
G/G 8 (15.69) 3 (6.25) 0.08 4.53 (1.03, 19.91)‡ G/G 19 (37.25) 26 (54.17) 0.11 1
P Homogeneity Test :0.01 P Homogeneity Test :0.01
Allelic
Female A allele 205 (68.79) 286 (64.13) 1 A allele 90 (30.20) 158 (35.43) 0.76 (0.55, 1.05)
G allele 93 (31.21) 160 (35.87) 0.19 0.79 (0.57, 1.08) G allele 208 (69.80) 288 (64.57) 0.14 1
Male A allele 61 (59.80) 72 (75.00) 1 A allele 41 (40.20) 25 (26.04) 1.97 (1.07, 3.62)
G allele 41 (40.20) 24 (25.00) 0.02 2.11 (1.14, 3.91) G allele 61 (59.80) 71 (73.96) 0.03 1
P Homogeneity Test :0.01 P Homogeneity Test :0.01
*P value were determined by chi-square test; P values less than 0.05 were considered significant
†Adjusted for diagnosis age and smoking history in unconditional logistic regression model
‡trend test is significant (p values = for trend tests were 0.0195 ** trend test is significant (p values = for trend tests were 0.0345.
Abbreviations: CI, confidence interval; GO, Graves’ ophthalmopathy; SNP, single-nucleotide polymorphism; OR, odd ratio.
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TLR-9 polymorphisms were associated with increase
the risk of GO in males in present study. In general, GD
is more common among women; however, male sex also
faces the risk of developing progressive and severe thyr-
oid-associated orbitopathy [4,7,4,7] or responds poorly
to treatment [40,38]. A previous study has reported a
female to male ratio of 9.3 for patients with mild GO
and of 3.2 for those with moderate GO, with the ratio
being 1.4 for patients with severe GO [4,4]. Our data
suggest that the role of TLR-9, which plays an impor-
tant role in conferring innate immunity, would be more
critical in men with GO. The susceptibility factor seems
to play a different role depending on sex, or the effect
could be more apparent in men and not in women
because of the difference in the basic immune responses
between the 2 sexes [41,39]. Further studies are required
to investigate that if the TLR-9 activity and its potential
relevance cytokines being more prone to male with GO.
As the smoking is potential confounding factor for
susceptibility of GO, we adjusted the variable of smok-
ing history in the multivariate model to eliminate the
smoking effect on susceptibility of GO. However, the
significant association between TLR-9 gene polymorph-
ism and susceptibility to GO in the male patients was
no changed. Furthermore, the strength association
between TLR-9 polymorphism and GO in male was
modest in present study. Therefore, a larger sample
sized, especially in male population will be needed in
the future study to confirm the importance of these
polymorphisms as genetic markers of GD in Taiwanese
population. Furthermore, the interpretation of our study
results is limited because the patients were recruited
from Taiwan only. Studies in ethnically disparate popu-
lations are needed before firm conclusions can be
drawn.
Conclusion
In conclusion, our findings suggested that TLR-9 gene
polymorphisms were significantly associated with sus-
ceptibility to GO in the male GD patients in Taiwan.
Additional material
Additional file 1: Table S1: Power calculation using GPower 3.1
software. Power calculation using GPower 3.1 software.
Additional file 2: Table S2: Genotype Frequency of TLR-4 and TLR-9
Markers for Graves’ Disease Patients in Taiwan. The results of
comparisons of TLR-4 and TLR-9 genotype frequency between the
Graves’ Disease patients with and without Ophthalmopathy.
Additional file 3: Table S3: Allelic Frequency of TLR-4 and TLR-9
Genes for Graves’ Disease Patients in Taiwan. The results of
comparisons of TLR-4 and TLR-9 allelic frequency between the Graves’
Disease patients with and without Ophthalmopathy.
Additional file 4: Table S4: Characters of Male Graves’ Disease
Patients with Ophthalmopathy and without Ophthalmopathy.
Characters of Male Graves’ Disease Patients with and without
Ophthalmopathy.
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